[
    {
        "molecule_name": "1 (trans-compound)",
        "protein_target_name": "EGFR",
        "binding_metric": "IC50",
        "value": "11",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the IC50 that compound of Formula I of the present invention demonstrates＜10 μ M, preferred＜1 μ M.\nCompound (embodiment number)EGFR-dependency inhibition of proliferation IC\n                      <sub>50</sub>[nM]\n                    1 (trans-compound)??11 (1) (trans-compound)??11 (3) (trans-compound)??11 (5) (trans-compound)??1??(36)??1??(44)??1"
    },
    {
        "molecule_name": "3 (trans-compound)",
        "protein_target_name": "EGFR",
        "binding_metric": "IC50",
        "value": "11",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the IC50 that compound of Formula I of the present invention demonstrates＜10 μ M, preferred＜1 μ M.\nCompound (embodiment number)EGFR-dependency inhibition of proliferation IC\n                      <sub>50</sub>[nM]\n                    1 (trans-compound)??11 (1) (trans-compound)??11 (3) (trans-compound)??11 (5) (trans-compound)??1??(36)??1??(44)??1"
    },
    {
        "molecule_name": "5 (trans-compound)",
        "protein_target_name": "EGFR",
        "binding_metric": "IC50",
        "value": "11",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the IC50 that compound of Formula I of the present invention demonstrates＜10 μ M, preferred＜1 μ M.\nCompound (embodiment number)EGFR-dependency inhibition of proliferation IC\n                      <sub>50</sub>[nM]\n                    1 (trans-compound)??11 (1) (trans-compound)??11 (3) (trans-compound)??11 (5) (trans-compound)??1??(36)??1??(44)??1"
    },
    {
        "molecule_name": "36",
        "protein_target_name": "EGFR",
        "binding_metric": "IC50",
        "value": "1",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the IC50 that compound of Formula I of the present invention demonstrates＜10 μ M, preferred＜1 μ M.\nCompound (embodiment number)EGFR-dependency inhibition of proliferation IC\n                      <sub>50</sub>[nM]\n                    1 (trans-compound)??11 (1) (trans-compound)??11 (3) (trans-compound)??11 (5) (trans-compound)??1??(36)??1??(44)??1"
    },
    {
        "molecule_name": "44",
        "protein_target_name": "EGFR",
        "binding_metric": "IC50",
        "value": "1",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "For example, the IC50 that compound of Formula I of the present invention demonstrates＜10 μ M, preferred＜1 μ M.\nCompound (embodiment number)EGFR-dependency inhibition of proliferation IC\n                      <sub>50</sub>[nM]\n                    1 (trans-compound)??11 (1) (trans-compound)??11 (3) (trans-compound)??11 (5) (trans-compound)??1??(36)??1??(44)??1"
    }
]